You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Kesimpta

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Not yet recruiting
  • Multiple Sclerosis
  • Multiple sclerosis disease modifying drug
  • (no location specified)
Nov 27, 2023

Kesimpta (Ofatumumab) Pregnancy Registry

Recruiting
  • Multiple Sclerosis
  • Pregnancy
  • Kesimpta
  • La Jolla, California
    Novartis Investigative Site
Jan 16, 2023

From Patient and Care Partner on Injection and Device for

Recruiting
  • Multiple Sclerosis
  • Kesimpta
  • East Hanover, New Jersey
    Novartis Investigative Site
Jan 31, 2023

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Kesimpta® Treatment Effects in Relapsing Multiple Sclerosis

Recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • Bamberg, Bavaria, Germany
  • +21 more
Jan 25, 2023

Ofatumumab in Portuguese Multiple Sclerosis Patients

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 30, 2023

Kesimpta® in Swiss Multiple Sclerosis Patients -Observational

Recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • Baden, Aargau, Switzerland
  • +17 more
Jan 20, 2023

Quality of Life of Multiple Sclerosis Patients Treated With

Not yet recruiting
  • Multiple Sclerosis (MS)
  • ofatumumab
  • (no location specified)
Nov 27, 2023

The 'Wearing Off' Effect of DMT

Recruiting
  • Multiple Sclerosis
  • ocrelizumab
  • +2 more
  • Basel, Switzerland
    Novartis Investigative Site
Jan 24, 2023

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Los Angeles, California
    University of Southern California
Feb 3, 2022

Kesimpta for s.c. Injection 20 mg Pen

Recruiting
  • Relapsing-remitting Multiple Sclerosis
  • Active Secondary Progressive Multiple Sclerosis
  • Kesimpta
  • Ichinomiya, Aichi, Japan
  • +121 more
Jan 13, 2023

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Highly Effective Therapies Group
  • Escalation Therapies Group
  • Aurora, Colorado
  • +30 more
Jul 22, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

COVID-19 Vaccine Response in Treated MS Patients

Recruiting
  • Multiple Sclerosis
  • Healthy
  • Blood draw
  • Boston, Massachusetts
    Brigham MS Center
Jul 26, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Aggressive Therapy or Traditional Therapy
  • Birmingham, Alabama
  • +51 more
Jan 23, 2023